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Available online 20 May 2016Background:High serum levels of the inﬂammatory biomarker soluble urokinase plasminogen activator receptor
(suPAR) have been associated with poor neurological outcome in patients after cardiac arrest (CA), but with in-
adequate and contradictive prediction values. The purpose of this study was to provide further evidence on the
prognostic value of suPAR for the prediction of poor neurological outcome after initially survived CA.
Methods: A total of 177 patients were prospectively enrolled in this cohort study. 85 patients with survived CA
were included and the neurological outcome was assessed after 6 months. 71 patients with ST-segmental eleva-
tion myocardial infarction (STEMI) and 21 healthy control patients served as comparative groups.
Results: The serum suPAR levels on admission and the subsequent serum course were signiﬁcantly higher in pa-
tientswith CA as compared to STEMI and control patients. Furthermore, patientswith poor neurological outcome
showed signiﬁcantly higher serum suPAR levels as compared to patients with good neurological outcome. By the
use of ROC-curves and setting the speciﬁcities to 100%, inadequate sensitivities and cut-off valueswere calculated
(day 2: sensitivity 21.1%, cut-off 10.2 ng/dl, AUC 0.716). By setting the speciﬁcities to at least 80% the best predic-
tion values could be calculated for day 2 with a sensitivity of 57.9% and a cut-off value of 5.3 ng/dl.
Conclusions: SuPAR serum levels in patients with poor neurological outcome were signiﬁcantly higher as
compared to patients with good neurological outcome. However, the prognostic value was low and inadequate
because of a substantial overlap of serum suPAR levels between the outcome groups.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Modiﬁed Glasgow Outcome Score (MGOS)1. Introduction
Myocardial infarction and sudden cardiac arrest (CA) are the leading
causes of death in Europe and the USA [1]. The improved rates of resto-
ration of spontaneous circulation (ROSC) after cardiopulmonary resus-
citation (CPR) resulted in an increasing number of patients suffering
from various degrees of brain damage [2]. Furthermore, ROSC following
CA causes a complex ischemia–reperfusion injury with activation of a
complex systemic inﬂammation, coagulation and ﬁbrinolysis resulting
in increased levels of circulating plasma cytokines and endotoxins [3,4].ability and freedom from bias of
spital, Department of Cardiac
ermany.
na).
land Ltd. This is an open access articlUrokinase plasminogen activator (uPA) is a serine protease that has
been implicated in a variety of physiological and pathophysiological
processes. For example, uPA is known to activate extracellular matrix
degrading enzymes and induces intracellular signaling pathways regu-
lating cell adhesion and migration [5]. In addition, the uPA system has
been implicated in the pathogenesis of ischemia–reperfusion injury
[6]. The uPA-receptor (uPAR) is expressed on different cell types includ-
ing neutrophils, lymphocytes, monocytes, macrophages and vascular
endothelial cells [7]. Through inﬂammatory stimulation uPAR is cleaved
from the cell surface by proteases to the soluble form of the receptor
(suPAR), which can be detected in the blood of patients [8]. Increased
suPAR blood concentrations could be detected in various infectious dis-
eases and tumors [9,10]. Moreover, suPAR has been identiﬁed as a bio-
chemical marker to indicate poor outcome in patients with systemic
inﬂammatory response syndrome (SIRS) and sepsis [11].
Recently, it has been demonstrated that high levels of suPAR were
associated with poor outcome in patients with out-of-hospital CA, bute under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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was low and inadequate [12,13]. Furthermore, the time points of blood
sample collection for themeasurement of suPARwere limited to the 3rd
and 4th day after ICU admission, respectively [12,13]. Hence, the pres-
ent study was conducted to provide further information on suPAR
serum concentrations as a predictor for poor neurological outcome in
patients after CA. The blood samples were collected on 5 different
time points (on admission, 2nd day, 3rd day, 5th day and 7th day after
admission) and the neurological outcome was assessed after 6 months.
Additionally, and to serve as a comparison, suPAR serum concentrations
were measured in a control cohort and in patients after ST-segment
elevation myocardial infarction (STEMI).
2. Methods
2.1. Study design and patients
Patients were enrolled in this study between March 2009 and June
2011 at the intensive care unit (ICU) of the RWTH Aachen University
Hospital Germany in a prospective manner. Approval for the study
was obtained from the ethics committee at the RWTHAachen Universi-
ty Hospital Germany in accordancewith the international guidelines for
Good Clinical Practice. The cohort data and serum samples of the pa-
tients with CA (n= 85) used in this study have previously been evalu-
ated for the biochemical serummarker neuroﬁlament light chain (NF-L)
to predict poor neurological outcome in patients with CA [2]. Serum
samples for the determination of suPAR levels in patients with CA
were taken within 2 h (day 1) after admission, as well as on days 2, 3,
5 and 7 after admission. Accordingly, serum samples for the measure-
ment of suPAR in patients with STEMI (n = 71) were collected before
percutaneous coronary intervention (PCI, day 1), as well as on days 2,
3 and 5 after admission. As a control populationwe analyzed 21 healthy
blood donors with normal blood values. The neurological outcome of
patients with CA was assessed 6 months after CPR by employing the
Glasgow Outcome Score (GOS) and the Modiﬁed Glasgow Outcome
Score (MGOS) [14].
2.2. Standard care
All patients with STEMI and CAwere admitted to the ICU,monitored
and treated according to international standards. Patients with docu-
mented ST-segment elevation in the ECG underwent coronary angiog-
raphy and PCI as soon as possible. All patients with CA were intubated
and mechanically ventilated. Patients were sedated using midazolam
and/or propofol and received adequate analgesia with fentanyl. The
procedure of mild hypothermia was performed according to interna-
tional standards with the CoolGard 3000 (Zoll®, USA) and Hilotherm
Clinic (Hilotherm® GmbH, Germany) cooling systems [14,15]. Vasoac-
tive or inotropic support, usually norepinephrine or dobutamine was
administered if necessary.
2.3. Neurological outcome and assessment of brain damage
Cerebral functionwas evaluated 6months after CA by employing the
GOS as described by Jennett and Bond [16] and the modiﬁed GOS a
described previously [14].
For statistical purposes, outcome categories of both scores were split
into 2 to 3 groups:
GOS:
poor: consisted of patients who died of any cause or remained in a
persistent vegetative state (GOS 1–2)
good: consisted of patients who regained consciousness (GOS 3–5)
MGOS:
unclear: consisted of patients who died of any cause without docu-
mented brain damage (MGOS 0)poor: consisted of patients who died with certiﬁed brain damage or
remained in a persistent vegetative state (MGOS 1–2)
good: consisted of patients who regained consciousness (MGOS 3–
5 = GOS 3–5).
Brain damage was assessed as described previously [2,14,17].
2.4. suPAR measurements
Blood samples were taken from patients and collected in a standard
serum tube on time points as described above. Samples were immedi-
ately centrifuged for 10 min at 1500 g and serum aliquots were frozen
immediately at −20 °C. suPAR serum concentrations were analyzed
using a commercial enzyme immunoassay (ViroGates, Birkeroed,
Denmark) as described previously [11].
2.5. Statistical analysis
Data are presented asmedian and quartiles due to the skeweddistri-
bution of most of the parameters. Differences between 2 groups were
assessed by the Mann–Whitney-U-test and comparisons between
more than 2 groups have been conducted by the Kruskal–Wallis-H-
test and Mann–Whitney-U-test for post-hoc analysis. Box plot graphics
illustrate comparison between the groups and subgroups and they dis-
play a statistical summary of themedian, quartiles, upper whiskers 95%,
lower whiskers 5%, minimum/maximum values and the means. All
values have been included for statistical analysis without excluding
the outliers. Statistical analysis of longitudinal measurements of suPAR
levels have been conducted by the Friedman test. The receiver operating
characteristic (ROC) curve analysis and thederived area under the curve
(AUC, c-statistic)were used to provide a global and standardized appre-
ciation of the accuracy of suPAR for predicting poor neurological out-
come [18]. ROC curves were generated by plotting the sensitivity
against 1-speciﬁcity. A p value b 0.05 was considered as signiﬁcant. Sta-
tistical analysis was performedwith the IBM SPSS Statistics 20 Software
for Windows.
3. Results
3.1. Baseline characteristics
The baseline characteristics of the patients enrolled in this study are
shown in Table 1. The healthy control group was signiﬁcantly younger
as compared to the group of STEMI or CA. Furthermore, the O2 and
CO2 partial pressure, lactate, pH, blood glucose and serum creatine ki-
nase on admissionwere signiﬁcantly higher in patients with CA as com-
pared to STEMI patients. In addition, coronary heart disease in the past
medical history was more frequently present in patients with CA as
compared to the control groupor patientswith STEMI. No further signif-
icant differences were observed among the groups.
3.2. suPAR serum concentrations upon admission
Upon admission, patients with STEMI demonstrated signiﬁcantly
higher levels of suPAR as compared to control patients (median —
min — max — range —mean (ng/ml): control 1.7 — 0.6 — 2.5 — 1.9 —
1.55, STEMI 2.7— 0.8— 13.8— 13— 3.42, p b 0.001) (Fig. 1). In analogy,
patients that initially survived CA showed signiﬁcantly higher values
of suPAR as compared to control patients (median — min — max —
range —mean (ng/ml): control 1.7 — 0.6 — 2.5 — 1.9 — 1.55, CA 4.1 —
0.7 — 19.4 — 18.7 — 5.24, p b 0.001). In addition, comparison of
suPAR serum levels of patientswith STEMI and CA revealed signiﬁcantly
higher levels of suPAR in patients with CA as compared to STEMI
(median — min — max — range — mean (ng/ml): STEMI 2.7 — 0.8 —
13.8 — 13— 3.42, CA 4.1 — 0.7 — 19.4 — 18.7 — 5.24, p b 0.001).
Table 1
Baseline characteristics of patients.
Parameters (unit) ± SD Control (1)
(n = 21)
STEMI (2)
(n = 71)
CA (3)
(n = 85)
p value
1 vs. 2
p value
2 vs. 3
p value
1 vs. 3
Sex (male/female) 15/6 54/17 72/13 0.816 0.913 0.871
Age (years) 45.2 ± 15.4 63.1 ± 11.3 65.6 ± 14.2 b0.001 0.945 b0.001
On admission
O2 partial pressure (mm Hg) 163.3 ± 96.2 234 ± 169.4 0.008
CO2 partial pressure (mm Hg) 38 ± 9.7 46.4 ± 19.2 0.002
Lactate (mmol/l) 2 ± 1.6 6.2 ± 4.5 b0.001
pH 7.38 ± 0.11 7.23 ± 0.2 b0.001
Blood glucose (mmol/l) 9.2 ± 4.1 13.1 ± 5.9 b0.001
Serum creatinine (mg/dl) 0.91 ± 0.54 1.39 ± 1.2 0.002
APACHE II 31.9 ± 5.8
Time of hypoxia (min) 8.8 ± 3.5
Mean duration of CPR (min) 27.3 ± 27.8
Bystander-initiated CPR (min) 1.3 ± 3
Deﬁbrillations before ROSC 2.5 ± 3.4
Epinephrine dose before ROSC (mg) 3.7 ± 3
Hypothermia — no./total no. (%) 63/85 (74)
Days of mechanical ventilation 9.5 ± 10.1
First ECG no./total no. (%)
Ventricular ﬁbrillation 51/85 (60)
Ventricular tachycardia 2/85 (2)
Asystole 23/85 (27)
Other rhythm 9/85 (11)
Past medical history no./total no. (%)
Diabetes 3/21 (14) 9/71 (13) 20/85 (24) 0.985 0.163 0.552
Coronary heart disease 2/21 (10) 14/71 (20) 34/85 (40) 0.544 0.012 0.009
Cerebrovascular disease 0/21 (0) 3/71 (4) 8/85 (9) 0.763 0.353 0.237
Peripheral artery disease 0/21 (0) 6/20 (30) 9/85 (11) 0.550 0.662 0.234
CA: cardiac arrest, APACHE: Acute Physiology and Chronic Health Evaluation, CPR: cardiopulmonary resuscitation, ROSC: restoration of spontaneous circulation.
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anterior (RIVA), ramus circumﬂexus (RCX) and right coronary artery
(RCA) associated STEMI and analyzed the serum concentrations of
suPAR on admission. Although patients with RCA- and RCX-STEMI dem-
onstrated higher serum suPAR levels as compared to RIVA-STEMI pa-
tients, the elevation did not reach statistical signiﬁcance when
compared to RIVA-STEMI patients (median — min — max — range —Fig. 1. suPAR serum levels in patients with CA, STEMI and healthy subjects. Box plots
showing suPAR serum levels on admission in healthy subjects (n = 21), patients with
STEMI (n = 52) and CA (n = 84). Serum suPAR levels were signiﬁcantly elevated (p b
0.001, Mann–Whitney-U-test) in patients with STEMI and CA as compared to healthy
controls. Furthermore, patients with CA demonstrated signiﬁcantly higher suPAR levels
as compared to STEMI patients (p b 0.001, Mann–Whitney-U-test). □ body of box with
range from ﬁrst to third quartile, - horizontal line in the box represents the median, ┬
upper whisker with 95%, ┴ lower whisker with 5%, ■ mean of all data, ● minimum/
maximum data point, ○ data points.mean (ng/ml): RCA 3.1 — 0.8 — 13.8 — 13 — 4.04, RIVA 2.4 — 1.3 —
4.9 — 3.6 — 2.54, RCX 3.1 — 1.6 — 7.2 — 5.6 — 3.58, p n.s.) (Fig. 2).
In addition, on admission suPAR serum levels were measured in
patients with CA, and the neurological outcome was evaluated after
6 months according to the Glasgow Outcome Score (GOS) and the
Modiﬁed Glasgow Outcome Score (MGOS) as described in the method
section. Patients with poor neurological outcome, either assessed by
the GOS or the MGOS, demonstrated signiﬁcantly higher suPAR levels
as compared to patients with good neurological outcome (median —
min — max — range — mean (ng/ml): GOS/MGOS good 3.9 — 0.7 —
10.9 — 10.2 — 4.18, GOS poor 5.2 — 0.9 — 19.4 — 18.5 — 6.29, MGOS
poor 5.9 — 2 — 12.7 — 10.7 — 6.41) (Fig. 3). However, in contrast toFig. 2. suPAR serum levels in patients with STEMI. Box plots demonstrating patients with
RCA (n = 27), RIVA (n = 20) and RCX (n = 5) associated STEMI on admission. No
statistical signiﬁcance was observed among the groups. □ body of box with range from
ﬁrst to third quartile, - horizontal line in the box represents the median, ┬ upper
whisker with 95%, ┴ lower whisker with 5%, ■mean of all data, ●minimum/maximum
data point, ○ data points.
.Fig. 3. suPAR serum levels in patients with CA. Box plots illustrating suPAR levels on
admission in patients with good (n = 42) and poor neurological outcome as assessed
6 months after CA by the use of the GOS (n = 42) and MGOS (n = 18). Patients with
poor neurological outcome demonstrated signiﬁcantly higher serum suPAR levels as
compared to patients with good neurological outcome. However, no signiﬁcant
differences were found when comparing both poor outcome groups to each other.
□ body of box with range from ﬁrst to third quartile, - horizontal line in the box
represents the median, ┬ upper whisker with 95%, ┴ lower whisker with 5%, ■mean of
all data,●minimum/maximum data point,○ data points.
Fig. 4. suPAR serum course of patients with STEMI and CA. A) Demonstrates the serum
course of suPAR in patients with STEMI over a time period of 5 days. There was a
tendency towards rising suPAR levels in longitudinal measurements, but serum suPAR
concentrations did not signiﬁcantly change within the ﬁrst 5 days after STEMI
(Friedman test, p = 0.092). B) In contrast, the serum suPAR levels in patients with CA,
either the total cohort (not shown) or their subgroups, signiﬁcantly increased during
the course of disease within the ﬁrst week (Friedman test, p b 0.001). ■/▲ mean of
values, ┬/┴ SEM.
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light chain (NF-L) [2,14], no signiﬁcant differences in suPAR serum
levels were found among the patients with poor neurological outcome
when compared GOS with MGOS.
3.3. suPAR serum course in patients with STEMI and CA
We next investigated whether suPAR levels changed in patients
with STEMI during the ﬁrst 5 days after admission and in patients
with CAwithin the ﬁrstweek of ICU treatment.We found a tendency to-
wards rising suPAR levels in patients with STEMI in longitudinal mea-
surements, but serum suPAR levels did not signiﬁcantly change within
the ﬁrst 5 days (Friedman test, p = 0.092) (Fig. 4A). This observation
was made for the total cohort of patients with STEMI, as well for their
subgroups (data not shown).
In contrast, the suPAR serum levels of patients with CA demonstrat-
ed a signiﬁcant increase in longitudinal measurements during the ﬁrst
week after ICU admission (Friedman test, p b 0.001). This time-
dependent elevation of suPAR could also be conﬁrmed for the sub-
groups of patients with CA (Fig. 4B). These data show that the initial
serum suPAR elevation in patients with STEMI and CA remains stable
elevated during the studied time course with a signiﬁcant increase in
patients with CA.
3.4. Prediction power of suPAR for poor neurological outcome
Next, wemeasured cut-off values, sensitivities and AUCby the use of
ROC analysis. Initially, the speciﬁcity was set to 100% for the prediction
of poor outcome of suPAR for each day, respectively. The group of poor
outcome comprised patients who died of any reason, either with docu-
mented brain damage or without, and patients who remained in the
vegetative status (GOS 1 + 2). All other patients were categorized in
the group of patients with good neurological outcome (GOS 3 + 4 + 5)
The calculated sensitivities for the prediction of poor outcome
remained below 20% for all measured time points with the exception
of suPAR levels of day 1 (sensitivity 21.1%) (Table 2). In order tocalculate best prediction values for suPAR the speciﬁcity was set to at
least 80% and the sensitivities were calculated again. Hereby, the calcu-
lated sensitivities rose up to 57.9% (day 2) (Table 3). The ROC curve of
suPAR for day 2 is depicted in Fig. 5.
4. Discussion
Themajor ﬁndings of the present study are 1) after CA, serum suPAR
levels are signiﬁcantly increased in patients with poor neurological
outcome as compared to patients with good neurological outcome,
2) suPAR could be conﬁrmed as an early serum prediction marker for
long-term neurological outcome in patients after CA, but with inade-
quate predictive values, 3) suPAR serum levels in patients with STEMI
are signiﬁcantly higher as compared to control patients and signiﬁcantly
lower as compared to patients with CA, 4) the suPAR serum course
remains stable in patients with STEMI and increases signiﬁcantly in
patients with CA over a period of 7 days.
In analogy to previous studies investigating the role of suPAR as a
predictive marker for the neurological outcome in patients surviving
Table 2
Cut-off points, sensitivities and AUC values of suPAR serum levels predicting poor outcome with 100% speciﬁcity.
Cut-off value Speciﬁcity Sensitivity AUC 95% CI of AUC p value
suPAR day 1 11 100 9.5 0.690 0.578–0.803 0.003
suPAR day 2 10.2 100 21.1 0.716 0.565–0.867 0.012
suPAR day 3 12.5 100 13.3 0.733 0.570–0.897 0.015
suPAR day 5 12.7 100 13.3 0.693 0.524–0.862 0.041
suPAR day 7 11.8 100 18.8 0.748 0.593–0.903 0.006
AUC: area under the curve; CI: conﬁdence interval.
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tients with poor neurological outcome as compared to patients with
good neurological outcome. In line with the studies of Jalkanen et al.
[12] and Rundgren et al. [13], we could calculate fair prediction values
for suPAR to predict poor outcome in our cohort of patients with CA
(suPAR serum level day 2: sensitivity 58%, speciﬁcity 80%, AUC 0.716,
n = 85).
Jalkanen et al. demonstrated that high suPAR concentrations were
associated with poor outcome in patients with CA. However, they
concluded that suPAR alone had inadequate predictive value for poor
outcome and did not associate with 12 month neurological outcome
according the GP-CPC [5]. Jalkanen et al. reported of a sensitivity of
65%, speciﬁcity of 76% and an AUC of 0.75 for the prediction of poor out-
come (GP-CPC 3–5) of baseline suPAR. Details of the sensitivities and
speciﬁcities of the other days (day 1, day 2 and day 4) were not provid-
ed. However, the best AUC value which Jalkanen et al. reported was for
baseline suPAR with 0.75. This is in line with our ﬁndings with a best
calculated AUC of 0.748 on day 7.
Rundgren et al. performed a study with 55 CA patients in which
they demonstrated that suPAR levels were signiﬁcantly higher in
nonsurviving patients compared with survivors at 6 and 36 h, but not
at 72 h. Furthermore, they reported that suPAR levels signiﬁcantly in-
creased from 6 to 72 h, which is in line with our ﬁndings. They reported
of an AUC of 0.76 at 6 h by the use of ROC curve analyses.
Our group could demonstrate thatwith the use of theGOS or the GP-
CPC the calculated prediction power of the neurological markers
NSE and S100B with respect to sensitivities and AUC values is
underestimated as compared with the modiﬁed outcome score, which
we termed as MGOS [14]. This bias is mainly created, because patients
who died with an unclear neurological status were not excluded from
the group of patients with poor outcome in the GOS and GP-CPC. How-
ever, in this study, we could found no signiﬁcant difference in suPAR
levels when comparing both groups with poor outcome (GOS 1–2 vs.
MGOS1–2, Fig. 3). This ismainly because suPAR is amore ubiquitous in-
ﬂammatory marker rather than a more selective brain damage marker,
as it is the case with NSE, S100B and NF-L.
To be an ideal predictive marker for global hypoxic brain damage or
injury in patients with CA, a marker should be speciﬁcally and exclu-
sively expressed and proved to be released from neurons. However,
up to now, this exclusive criteria for an ideal marker is only present in
NF-L and neuroﬁlament heavy chain (NF-H) [2,19]. For NF-L on
admission, we could demonstrate excellent predictive values with an
AUC of 0.93, a sensitivity of 79% and a speciﬁcity of 100% [2]. However,
Rundgren et al. demonstrated lower prediction values for NF-H in
their cohort of patients with CA (serum NF-H at 2 h: AUC 0.72) [19].Table 3
Cut-off points, sensitivities andAUC values of suPAR serum levels predictingpoor outcome
with at least 80% speciﬁcity.
Cut-off value Speciﬁcity Sensitivity
suPAR day 1 5.6 81 45.2
suPAR day 2 5.3 80 57.9
suPAR day 3 6.7 84 33.3
suPAR day 5 7.7 81.5 40
suPAR day 7 7.3 80 50Shinozaki et al. emphasized to set the speciﬁcity to 100% when in-
vestigating biochemical markers for the prediction of poor outcome in
patients with CA [20]. By following this recommendation, the calculated
average sensitivities of suPAR were extremely low and thereby not ap-
plicable for clinical utility. In analogy, the calculated cut-off values with
100% speciﬁcities were extremely high because of a substantial overlap
of suPAR levels in numerous patients with good (range 10.2 ng/ml) and
poor (range 18.5 ng/ml) neurological outcome. Because suPAR is not a
speciﬁc brain damage marker rather an inﬂammatory marker, the au-
thors of this study recommend to set the speciﬁcity to at least 80% to cal-
culate clinically applicable cut-off values with fair sensitivities. Hence,
the calculated sensitivity rose up to 58% for suPAR serum levels on day
2 with a calculated cut-off value of 5.3 ng/ml, which is, to our opinion,
a representative cut-off value for the prediction of poor outcome in pa-
tients after CA. However, its reclusive application as a biomarker to pre-
dict poor outcome in CA patients had inadequate predictive values with
sensitivities far below 50%. Thus, suPAR is a drawback for the exclusive
use in clinical routine. However, suPAR serum levels below the cut-off
values may indicate favorable neurological outcome (N80% speciﬁcity)
and could be used, certainly with involvement of clinical representation
of the patient and combined with other biochemical markers such as
NSE or S100B, not to withdraw from further therapy. However, these
ﬁndings and suggestions require independent veriﬁcation in a multi-
center prospective cohort study.Fig. 5. ROC curve analysis of serum suPAR levels on day 2 for the prediction of poor
neurological outcome assessed by the GOS. The red solid circle marks the serum suPAR
cut-off point with 80% speciﬁcity and 57.9% sensitivity. suPAR cut-off values are given in
ng/ml. AUC denotes area under the curve.
13O.R. Rana et al. / IJC Metabolic & Endocrine 12 (2016) 8–135. Conclusions
suPAR could be conﬁrmed as an early serum prediction marker for
the long-term neurological outcome in patients after CA. The suPAR
serum levels in patients with poor neurological outcome were signiﬁ-
cantly higher as compared to patients with good neurological outcome.
However, the prognostic value was low and inadequate because of a
substantial overlap of suPAR levels between the outcome groups.
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